US › Healthcare

Evogene (EVGN)

US · Healthcare · Biotechnology

$0.50+0.66%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$347,000

Revenue YoY

-60.7%

Net profit

$-1.8M

EPS

$-0.13

EPS estimate

$-0.27

Net margin

-509.5%

EPS came in at -0.13 against a street estimate of -0.27 — a beat of 51.9%.

Key statistics

Market cap

$7.6M

Forward P/E

0.0

P/B

6.18

Book value

$-0.24

EPS (TTM)

$-1.68

52-week high

$1.50

52-week low

$0.37

50-day MA

$0.54

200-day MA

$0.78

Beta

0.70

Analyst view

Analysts rate Evogene a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $2.15.

Shareholding

Insiders

27.86%

Institutions

6.36%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	2.89%
Jane Street Group LLC	0.12%
XTX Topco Ltd	0.08%
TWO SIGMA SECURITIES, LLC	0.08%
Daytona Street Capital LLC	0.06%
BNP Paribas Arbitrage, SA	0.06%
UBS Group AG	0.04%
Morgan Stanley - Brokerage Accounts	0.02%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Evogene — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.